-
ABOUT USAffiliated to SSY Group Limited, Hebei Guangxiang Technology Co., Ltd., is a high-tech enterprise specializing in drug research and technology development.
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the synergy between “industry, academia, research and application” based on multi-disciplinary integration and multi-directional combination.
-
SUBORDINATEThe group has decided to establish research institutes in its subsidiaries, Hebei Ghuangxiang Drug Research Institute, Jiangsu Best Medical Material Research Institute, and Hebei Hanlin Biological Research Institute.
-
RECRUITWe actively establish a joint talent cultivation mechanism between schools and enterprises, and currently have over 500 high-level talents in various fields such as drug research, analysis, and clinical practice.
-
CONTACTWe will continue to strengthen innovation-driven development, vigorously promote the integration of production and research, constantly improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs.
Shi Si Pharmaceutical Group Ranks Among Top 25 on Hong Kong Stock Exchange’s List of Top 100 Pharmaceutical Companies.
Category:
Time：2023-02-25
On February 24, at the “Digital Transformation, Co-creating New Value” — 2022 Hong Kong Listed Companies Development Summit and the 10th “Hong Kong Stock 100” Awards Ceremony, hosted by the Hong Kong Stock 100 Research Center and co-organized by Caihua Society, Futu AnYi, and Dongshi Technology, Shisi Pharmaceutical Group was honored with a place among the top 25 on the Hong Kong Stock 100 Pharmaceutical List.
On February 24, at the “Digital Transformation, Co-creating New Value” — 2022 Hong Kong Listed Companies Development Summit and the 10th “Hong Kong Stock 100” Awards Ceremony, hosted by the Top 100 Hong Kong Stocks Research Center and co-organized by Caihua Society, Futu AnYi, and Dongshi Technology, Shisi Pharmaceutical Group was honored with a place among the top 25 on the Hong Kong Stock 100 Pharmaceutical List.
As one of the backbone enterprises in China’s pharmaceutical industry, Shiyao Group has seized the development opportunities brought about by shifts in industrial structure and market dynamics. Focusing on the dual circulation strategy—both domestic and international—it continues to accelerate its innovation ecosystem layout and product development across key areas such as specialty generic drugs, active pharmaceutical ingredients, innovative medicines, and pharmaceutical packaging materials. This proactive approach has effectively promoted optimization of its product portfolio and enhanced both quality and efficiency of development, earning widespread recognition and attention from both product and capital markets through outstanding performance.
The “Top 100 Hong Kong Stocks” selection event was launched in 2012, jointly initiated by Tencent and Caihua News Agency. Each year, the event uses precise data and a series of scientifically sound evaluation criteria to identify outstanding Hong Kong-listed companies, publish the ranking list, and present awards. The purpose of this event is to recognize Hong Kong main-board listed companies that demonstrate robust growth and possess investment value, thereby promoting the healthy and prosperous development of Hong Kong’s capital market. At the same time, the event combines a high-level summit forum with an awards ceremony for listed companies, providing a platform for discussing financial market trends and economic developments. The number of participants and supporting organizations continues to grow, and the event’s influence expands year by year, making it one of the annual highlights in Hong Kong’s financial and business circles.
It is reported that the “Top 100 Hong Kong Stocks” has consistently been committed to creating a ranking of Hong Kong-listed companies that emphasizes both authority and credibility. Guided by the principles of professionalism, objectivity, fairness, and accuracy, the ranking is compiled through an impartial selection panel, seasoned advisory expertise, in-depth professional analysis, and a fair, just, and highly credible evaluation mechanism, thereby identifying outstanding Hong Kong-listed companies and setting a new benchmark for investors. The objectivity of the ranking results has earned wide recognition and trust from both professional institutions and investors.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Mobile site
E code
Business license